Neuspera Medical’s Battery-Free Neuromodulation System Shows Promising Results in UUI Clinical Trial

Picture Credit | World Wide Web

Neuspera Medical, Inc., a leader in implantable neuromodulation technology, has announced groundbreaking six-month clinical trial results for its battery-free percutaneous sacral neuromodulation (PSNM) system designed to treat urgency urinary incontinence (UUI). The trial demonstrated significant improvements in symptom reduction, marking a major advancement in minimally invasive treatment options for patients suffering from bladder control disorders.

The study, known as SANS-UUI, evaluated the safety and effectiveness of Neuspera’s PSNM system, which utilizes a miniature, battery-free implant powered by an external wearable device. Key findings include:

• 85% of patients reported a clinically meaningful reduction in UUI episodes.
• No serious device-related adverse events, confirming a strong safety profile.
• A significant improvement in quality of life scores among participants.

“These results validate the potential of our battery-free PSNM system to provide patients with a less invasive, more comfortable, and effective alternative for managing UUI,” said Steinhubl, Chief Medical Officer of Neuspera Medical. “We are thrilled by the positive outcomes and look forward to advancing this technology toward regulatory approvals and commercial availability.”

Neuspera’s innovative PSNM system is designed to provide effective neuromodulation therapy with a minimally invasive approach, offering patients a discreet and flexible treatment option compared to traditional sacral neuromodulation devices.

With these promising clinical trial results, Neuspera Medical plans to pursue regulatory submissions, paving the way for expanded access to this breakthrough therapy for millions affected by UUI worldwide.